| NCT ID | NCT05007340 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Interstitial Lung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 252 participants |
| Start Date | 2021-08-24 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 252 participants in total. It began in 2021-08-24 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.
Eligibility Criteria
Inclusion Criteria: 1. Must be aged 18 years or older 2. Diagnosis of ILD as confirmed by a chest CT 3. Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD 4. Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures. Exclusion Criteria: N/A
Contact & Investigator
Christian Pineau, MD
PRINCIPAL INVESTIGATOR
McGill University Health Centre/Research Institute of the McGill University Health Centre
Frequently Asked Questions
Who can join the NCT05007340 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Interstitial Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05007340 currently recruiting?
Yes, NCT05007340 is actively recruiting participants. Contact the research team at deborah.assayag@mcgill.ca for enrollment information.
Where is the NCT05007340 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05007340 clinical trial?
NCT05007340 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The principal investigator is Christian Pineau, MD at McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 252 participants.